Continuous Activity Monitoring During Concurrent Chemoradiotherapy.
暂无分享,去创建一个
K. Mehta | S. Kalnicki | B. Rapkin | B. Halmos | V. Shankar | C. Guha | M. Haigentz | N. Ohri | M. Garg | W. Bodner | R. Kabarriti
[1] S. Kalnicki,et al. Radiation Therapy Noncompliance and Clinical Outcomes in an Urban Academic Cancer Center. , 2016, International journal of radiation oncology, biology, physics.
[2] J. Bergman,et al. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma , 2014, BMC Cancer.
[3] Jacqueline Esthappan,et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2013, International journal of radiation oncology, biology, physics.
[4] Jose Belderbos,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] G. Fountzilas,et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer , 2010, Cancer Chemotherapy and Pharmacology.
[6] J. Menzin,et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. , 2009, Archives of otolaryngology--head & neck surgery.
[7] Cynthia S. Johnson,et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Oster,et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma , 2006, Cancer.
[9] B E Ainsworth,et al. How many days of pedometer monitoring predict weekly physical activity in adults? , 2005, Preventive medicine.
[10] Y Ohno,et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer , 2001, British Journal of Cancer.
[11] S. Kudoh,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Ian N. Olver,et al. Observer error in grading performance status in cancer patients , 1999, Supportive Care in Cancer.
[13] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[14] C. Earle,et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] M. Lindstrom,et al. Loss of local control with prolongation in radiotherapy. , 1992, International journal of radiation oncology, biology, physics.
[16] T. Hutchinson,et al. Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. , 1979, Journal of chronic diseases.